Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
Type:
Application
Filed:
August 16, 2019
Publication date:
May 21, 2020
Applicant:
Quentis Therapeutics, Inc.
Inventors:
Joseph P. Vacca, Dansu Li, Sarah Bettigole
Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
Type:
Application
Filed:
December 1, 2017
Publication date:
September 12, 2019
Applicant:
Quentis Therapeutics, Inc.
Inventors:
Joseph P. Vacca, Dansu Li, Sarah Bettigole
Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
Type:
Grant
Filed:
May 31, 2018
Date of Patent:
August 27, 2019
Assignee:
Quentis Therapeutics, Inc.
Inventors:
Joseph P. Vacca, Dansu Li, Sarah Bettigole